PAX8 and thyroid cancer, nonmedullary, 2: Tumors having PAX8/PPARγ rearrangements commonly do not present RAS mutations, and this situation suggests that there are two independent pathways linked to PAX8/PPARγ translocations or RAS mutations that support the FTC development (42).